Retatrutide is an investigational triple receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from approved agents such as semaglutide or tirzepatide
The company called the HIMS product an unapproved, inauthentic, and untested knockoff and announced it would take legal and regulatory action to protect patients, our intellectual property and the integrity of the US gold-standard drug approval framework. This was not merely rhetorical
(Lausanne) 11 , 622589 (2020)
[DOI] [PMC free article] [PubMed] [Google Scholar] 233.Lele R., Haller S., David K., Gutierrez G., Rahmani S.K., Bailony M.R
Example letter contents included the text: Compounded drug products are not FDA-approved
Verchere, Torben Hansen, Fredrik Karpe, Jens J